Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guttmann NeuroRecovery – Intrathecal Wharton's jelly-derived MSCs and transcutaneous spinal cord stimulation in chronic spinal cord injury
2025-521877-14-00Phase 2Authorised
- Sponsor
- Institut Guttmann
- Start
- Jan 2026
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic viable Wharton's jelly-derived mesenchymal stem cells in acute spinal cord injury (SCI), sponsored by Institut Guttmann. Planned start Jan 2026; status: authorised.
02
Drugs
allogeneic viable Wharton's jelly-derived mesenchymal stem cells
03
Conditions
acute spinal cord injury (SCI)
Beyond the preview
Go deeper on 2025-521877-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521877-14-00.